Research programme: gene therapy - NanoCor TherapeuticsAlternative Names: BNP-CHF; Carfostin; Intracellular genetic protein therapy - NanoCor Therapeutics
Latest Information Update: 21 Apr 2016
At a glance
- Originator NanoCor Therapeutics
- Class Gene therapies
- Mechanism of Action Protein phosphatase 1 inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Heart failure